alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 801.110 Retail exemption for prescription devices.

A device subject to § 801.109 shall be exempt at the time of delivery to the ultimate purchaser or user from section 502(f)(1) of the act if it is delivered by a licensed practitioner in the course of his professional practice or upon a prescription or other order lawfully issued in the course of his professional practice, with labeling bearing the name and address of such licensed practitioner and the directions for use and cautionary statements, if any, contained in such order.
#### Anita H. Hartmann, Administratrix (Estate of William Wordie) *v.*Richard J. Smith et al., Trustees of the Property of the New York, New Haven and Hartford Railroad Company

*Irwin E. Friedman,*on the motion.

Submitted February 5

decided February 19, 1969

The motion by the plaintiff to amend her assignment of errors in the appeal from the Superior Court in New Haven County is granted.
**Exhibit 31.1**

 

**CERTIFICATION OF PRINCIPAL EXECUTIVEOFFICER**

 

**PURSUANT TO SECTION 302 OF THESARBANES-OXLEY ACT OF 2002**

 

I, James T. Engen, certify that:

 

1. I have reviewed this annual report on Form 10-K of LOUDTechnologies Inc.;

 

2.  Based on my knowledge, this report does notcontain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the period coveredby this report;

 

3. Based on my knowledge, the financial statements, andother financial information included in this report, fairly present in allmaterial respects the financial condition, results of operations and cash flowsof the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I areresponsible for establishing and maintaining disclosure controls and procedures(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrantand have:

 

(a)          Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under our supervision,to ensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

 

(b)         Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

 

(c)          Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during the registrant’smost recent fiscal quarter that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financialreporting; and

 

5.               The registrant’s othercertifying officer and I have disclosed, based on our most recent evaluation ofinternal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors:

 

(a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.

 
| Dated:   March 31, 2006 | By:      |    /s/ James T.  Engen                          |   |
|-----------------------------------|----------|-----------------------------------------------------------|--------|
|                              |     |   James T. Engen                                     |
|                              | * * | *   Chairman, President and Chief Executive Officer* |

 

----
Exhibit 12

                            PSEG ENERGY HOLDINGS INC.
               Computation of Ratios of Earnings to Fixed Charges

                                                         For the Six Months
                                                            Ended June 30,
                                                       2002               2001
                                                    ---------------------------
                                                       (thousands of dollars)
Earnings as Defined in
  Regulation S--K (A):
Pre-tax income from Continuing
  Operations .............................          (487,757)            97,780
(Income)/Loss from equity
  investees net of distributions .........           (14,455)           (32,415)
Fixed Charges ............................           113,605             84,098
Amortization of capitalized
interest .................................               445                159
Capitalized interest .....................            (4,881)           (10,262)
                                                    ---------------------------
Earnings .................................          (393,042)           139,360
                                                    ===========================

Fixed Charges as Defined in
  Regulation S--K (B):
Total interest expensed and
  capitalized ............................           112,158             82,606
Interest in rental expense ...............             1,447              1,492
                                                    ---------------------------
Total Fixed Charges ......................           113,605             84,098
                                                    ===========================

Ratio of Earnings to Fixed
  Charges (C) ............................             (3.46)              1.66
                                                    ===========================

(A)   The term "earnings" shall be defined as pre-tax income from continuing
      operations before adjustment for minority interests or income or loss from
      equity investees. Add fixed charges adjusted to exclude (a) the amount of
      any interest capitalized during the period, (b) amortization of
      capitalized interest and (c) distributed income of equity investees. From
      the total, subtract interest capitalized.

(B)   Fixed Charges represent (a) interest, whether expensed or capitalized, (b)
      amortization of debt discount, premium and expense, and (c) an estimate of
      interest implicit in rentals.

(C)   The ratio of Earnings to Fixed  Charges for the six months  ended June 30,
      2002  was  (3.46),  as noted  above,  which  represents  a  deficiency  of
      $506,647.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1250 Percutaneous catheter. ( a ) *Identification.* A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.1 Scope. ( a ) This part sets forth the classification of immunology and microbiology devices intended for human use that are in commercial distribution.
( b ) The indentification of a device in a regulation in this part is not a precise description of every device that is, or will be, subject to the regulation. A manufacturer who submits a premarket notification submission for a device under part 807 may not show merely that the device is accurately described by the section title and identification provisions of a regulation in this part, but shall state why the device is substantially equivalent to other devices, as required by § 807.87.
( c ) To avoid duplicative listings, an immunology and microbiology device that has two or more types of uses (e.g., used both as a diagnostic device and as a microbiology device) is listed only in one subpart.
( d ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
( e ) Guidance documents referenced in this part are available on the Internet at *http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm .*
[52 FR 17733, May 11, 1987, as amended at 68 FR 5827, Feb. 5, 2003; 79 FR 50552, Aug. 25, 2014]
Order entered July 30, 2014

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-14-00224-CR

No. 05-14-00225-CR

No. 05-14-00226-CR

WILLIAM PAUL HUDSON, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 416th Judicial District Court

Collin County, Texas

Trial Court Cause Nos. 416-82440-2011, 416-82442-2011, 416-82443-2011

ORDER

Appellant’s July 28, 2014 second motion for extension of time to file appellant’s brief is 

GRANTED. The time to file appellant’s brief is EXTENDED to August 8, 2014. If appellant 

fails to file his brief by the extended due date, this case will be abated for a hearing in the trial 

court regarding why appellant has not filed his brief.

/s/ LANA MYERS 

JUSTICE
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7604 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7604

To provide enhanced disaster unemployement assistance to victims of the 
           Hawaii wildfires of 2023, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 8, 2024

 Ms. Tokuda (for herself and Mr. Case) introduced the following bill; 
       which was referred to the Committee on Transportation and 
                             Infrastructure

_______________________________________________________________________

                                 A BILL

 
To provide enhanced disaster unemployement assistance to victims of the 
           Hawaii wildfires of 2023, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hawaii Wildfire Disaster 
Unemployment Assistance Continuity Act''.

SEC. 2. DISASTER UNEMPLOYMENT ASSISTANCE.

    Notwithstanding any other provision of law, in the case of an 
individual eligible to receive unemployment assistance under section 
410(a) of the Robert T. Stafford Disaster Relief and Emergency 
Assistance Act (42 U.S.C. 5177(a)) as a result of a disaster 
declaration made for the wildfires in Hawaii on August 8, 2023, the 
President shall make such assistance available for 39 weeks after the 
date of the disaster declaration.
                                 <all>
```
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 By Notice dated October 16, 2009, and published in the 
                    **Federal Register**
                     on October 28, 2009, (74 FR 55586), Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug
ScheduleTetrahydrocannabinols (7370)
I3,4-Methylenedioxymethamphetamine (MDMA) (7405)
ICocaine (9041)
IIOxycodone (9143)
IIHydrocodone (9193)
IIMethadone (9250)
IIDextropropoxyphene, bulk (non-dosage forms) (9273)
IIMorphine (9300)
II
 The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. No comments or objections have been received. DEA has considered the factors in 21 USC 823(a) and determined that the registration of Lin Zhi International Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 USC 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 26, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 2010-4719 Filed 3-4-10; 8:45 am] BILLING CODE 4410-09-P
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3765 Pit and fissure sealant and conditioner. ( a ) *Identification.* A pit and fissure sealant and conditioner is a device composed of resin, such as polymethylmethacrylate, intended for use primarily in young children to seal pit and fissure depressions (faults in the enamel) in the biting surfaces of teeth to prevent cavities.
( b ) *Classification.* Class II.
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000813897
<NAME> PSH MASTER L.P.I.
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                         978,683
<SECURITIES>                                         0
<RECEIVABLES>                                    2,929
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               981,612
<PP&E>                                           7,695
<DEPRECIATION>                                   7,695
<TOTAL-ASSETS>                                 981,612
<CURRENT-LIABILITIES>                            4,921
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     976,691
<TOTAL-LIABILITY-AND-EQUITY>                   981,612
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (21,520)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (21,520)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (21,520)
<EPS-PRIMARY>                                     0.01
<EPS-DILUTED>                                     0.01
        

</TABLE>
§ 74.3230 D&C Red No. 17. ( a ) *Identity and specifications.* The color additive D&C Red No. 17 shall conform in identity and specifications to the requirements of § 74.1317(a)(1) and (b).
( b ) *Uses and restrictions.* ( 1 ) The substance listed in paragraph (a) of this section may be used as a color additive in contact lens in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect.
( 2 ) Authorization for this use shall not be construed as waiving any of the requirements of section 510(k), 515, and 520(g) of the Federal Food, Drug, and Cosmetic Act with respect to the contact lens in which the color additive is used.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Red No. 17 shall be certified in accordance with regulations in part 80 of this chapter.
[55 FR 22898, June 5, 1990]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FINANCIAL
STATEMENTS INCLUDED IN FORM 10-QSB AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               JUN-30-1996
<CASH>                                         313,825
<SECURITIES>                                         0
<RECEIVABLES>                                  819,931
<ALLOWANCES>                                         0
<INVENTORY>                                    159,082
<CURRENT-ASSETS>                             1,292,838
<PP&E>                                       1,864,229
<DEPRECIATION>                                  74,785
<TOTAL-ASSETS>                               8,489,304
<CURRENT-LIABILITIES>                        1,882,998
<BONDS>                                      5,000,000
<PREFERRED-MANDATORY>                          739,696
<PREFERRED>                                     28,923
<COMMON>                                     6,961,387
<OTHER-SE>                                  (6,123,700)
<TOTAL-LIABILITY-AND-EQUITY>                 8,489,304
<SALES>                                      2,027,757
<TOTAL-REVENUES>                             2,027,757
<CGS>                                        1,039,069
<TOTAL-COSTS>                                1,039,069
<OTHER-EXPENSES>                             1,008,234
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             158,217
<INCOME-PRETAX>                               (164,183)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (164,183)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (164,183)
<EPS-PRIMARY>                                    (0.58)
<EPS-DILUTED>                                    (0.58)
        

</TABLE>
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4240 Cardiopulmonary bypass heat exchanger. ( a ) *Identification.* A cardiopulmonary bypass heat exchanger is a device, consisting of a heat exchange system used in extracorporeal circulation to warm or cool the blood or perfusion fluid flowing through the device.
( b ) *Classification.* Class II (performance standards).
§ 812.7 Prohibition of promotion and other practices. A sponsor, investigator, or any person acting for or on behalf of a sponsor or investigator shall not: ( a ) Promote or test market an investigational device, until after FDA has approved the device for commercial distribution.
( b ) Commercialize an investigational device by charging the subjects or investigators for a device a price larger than that necessary to recover costs of manufacture, research, development, and handling.
( c ) Unduly prolong an investigation. If data developed by the investigation indicate in the case of a class III device that premarket approval cannot be justified or in the case of a class II device that it will not comply with an applicable performance standard or an amendment to that standard, the sponsor shall promptly terminate the investigation.
( d ) Represent that an investigational device is safe or effective for the purposes for which it is being investigated.
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10Q FOR
THE QUARTER ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                         474,140
<SECURITIES>                                         0
<RECEIVABLES>                                3,616,015
<ALLOWANCES>                                   399,000
<INVENTORY>                                  2,041,209
<CURRENT-ASSETS>                             5,877,589
<PP&E>                                       9,026,849
<DEPRECIATION>                               3,844,930
<TOTAL-ASSETS>                              11,713,625
<CURRENT-LIABILITIES>                        5,947,818
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           382
<OTHER-SE>                                   1,752,440
<TOTAL-LIABILITY-AND-EQUITY>                11,713,625
<SALES>                                      4,874,956
<TOTAL-REVENUES>                             4,874,956
<CGS>                                        4,890,279
<TOTAL-COSTS>                                4,890,279
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             735,780
<INCOME-PRETAX>                            (5,259,718)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (5,259,718)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (5,259,718)
<EPS-PRIMARY>                                   (0.15)
<EPS-DILUTED>                                   (0.15)
        

</TABLE>